The UC space is highly diversified with a number of molecules approved. In October 2023, the FDA approved Omvoh (mirikizumab), an interleukin-23 antagonist developed by Eli Lilly. It is indicated ...

Other significant developments include promising phase 3 trial results for alopecia areata and the FDA's approval of Omvoh, which, along with solid earnings, position the company favorably even as ...

The 69-year-old momager showed off a chic bob on Instagram on March 24, opting for longer locks than her usual signature pixie cut. She slicked her dark hair back and down, where it sat neatly ...

We recently published a list of 15 Dividend Zombies to Invest in. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other dividend zombies to ...

Data captured from pediatric patients revealed a relationship between high burden of common infection episodes in early life and increased risk for moderate to severe infections in later childhood ...

Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease, becoming the first drug in the class available in both intravenous and subcutaneous ...

This $14,000 refrigerator stopped making ice in less than a year. Not to mention it took Sub-Zero 10 months to send us the last 2 drawers that were supposed to be included when we got it.

This article delves into the three approved assets in this class – AbbVie’s Skyrizi (risankizumab), Eli Lilly’s Omvoh (mirikizumab), and J&J’s Tremfya (guselkumab) – and explores how ...

The last of the sub-4% five-year fixed rates ... It has cut a range of its other residential rates by up to 0.27 percentage points, and it has also cut selected offset mortgage deals by up to 0.53 ...

shows switching providers when you're out of contract could cut bills by up to £235 annually ... The changes mean it is introducing sub-5% rates for new buyers with just a 5% deposit.